100 billion US dollars diabetes drug market, dulaglutide compound growth rate of 124.2% in five years

Overview of diabetes

Definition of diabetes

Diabetes is caused by genetic and environmental factors, with abnormal glucose metabolism as the main performance of the disease. The absolute or relative lack of insulin content leads to metabolic disorders of carbohydrate, fat, protein and other substances is its direct impact on the body. Long term hyperglycemia will lead to serious complications of diabetes, including acute complications and chronic complications such as diabetes Diabetic ketoacidosis, diabetic neuropathy, diabetic nephropathy, etc. Diabetes can also be combined with a variety of chronic diseases, leading to organ dysfunction and failure, disability and even death. Poor glycemic control in the long-term course of diabetes is the main reason for its deterioration.

Classification of diabetes mellitus

Clinical common diabetes can be divided into four types: type 1 diabetes, type 2 diabetes, gestational diabetes, special type of diabetes. Among them, patients with type 1 and 2 diabetes are the most common, while patients with gestational diabetes and special types of diabetes are relatively less.

Study on disease epidemiology

Diabetes mellitus (DM) is the result of environmental factors and genetic factors. Type 2 diabetes mellitus (T2DM) accounts for 90% ~ 95% of DM cases. With the progress of social science and technology, the improvement of people's living standards, the change of diet structure, the aggravation of population aging and the change of natural environment, the prevalence of DM is on the rise.

According to the data sources of 111 countries, the International Diabetes Federation (IDF) estimates that there will be 415 million DM patients aged 20-79 in the world in 2015, and 5 million people may die of DM. The global total health cost caused by DM is estimated to be 673 billion US dollars, and three-quarters of DM patients live in low-income countries. By 2040, the number of DM patients aged 20-79 in the world is expected to increase to 642 million.

At present, the number of diabetes patients in China is estimated to be 118 million, ranking first in the world. 60% of diabetic patients have at least one complication, which can lead to serious consequences such as stroke, coronary heart disease, blindness, renal failure and amputation. However, the overall effectiveness of diabetes prevention and control in China is poor, and the diabetes management ability of primary medical institutions is uneven. The awareness rate, treatment rate and blood glucose control rate of diabetes are 38.6%, 35.6% and 33.0% respectively. The "three rates" of diabetes are low, which is recognized by who as an indispensable link in the control of diabetes. In 2017, the general office of the State Council issued the "China's medium and long term plan for the prevention and treatment of chronic diseases (2017-2025)" and stressed that by 2025, the number of patients with diabetes should reach 40 million, and the standardized management rate of patients with hypertension and diabetes should reach 70%.

Market competition pattern

Global market size

The global diabetes drug market showed a rapid growth trend from 2015 to 2019, and the growth rate slowed down in 2019. The sales volume reached US $95.35 billion, with a year-on-year growth of 8.1%; the compound growth rate was 9.8% from 2015 to 2019.

Market size in China

In line with the trend of global diabetes drug market, China's diabetes drug market has also shown a rapid growth trend in recent three years, with a sales volume of US $3.92 billion in 2019, a year-on-year growth of 9.0%; and a compound growth rate of 8.7% from 2015 to 2019.

Global diabetes drug market

In the early stage, oral hypoglycemic drugs such as metformin were used to control blood glucose. When the high-dose oral hypoglycemic drugs were used, patients with glycosylated hemoglobin still more than 7 needed insulin treatment.

Insulin is the most important part of the third and fourth line treatment, and the last line of defense for patients with diabetes. In recent years, non insulin drugs are increasing, but insulin drugs still occupy a large proportion of the market. The total amount of the top ten drugs for diabetes treatment in the world accounted for 61.5%, of which insulin glargine ranked the first in sales volume. The market share and market share decreased year by year from 2015 to 2019, with the sales volume reaching 9.88 billion yuan in 2019, accounting for 10.4%, and the five-year compound growth rate of - 4.8%. At the same time, dulaglutide shows a strong market ability. The sales volume and market share of dulaglutide increase sharply from 2015 to 2019. The annual sales volume in 2019 reaches 7.31 billion US dollars, accounting for 7.7%, and the five-year compound growth rate is 124.2%.

summary

Diabetes is a chronic and systemic metabolic disease, which means that it is a variety of metabolic disorders that can not be cured at present, including blood glucose, blood pressure, blood lipid, water and electrolyte. The World Health Organization (who) and the International Diabetes Federation (IGU) were founded in 1991. November 14 is the world diabetes prevention day. After 29 years, it reminds the whole people to strengthen the awareness and prevention of diabetes.

At present, diabetes is becoming younger, the number of patients is increasing year by year, and there is still a growth trend in the future. Insulin drugs account for 60% of the top 10 sales of diabetes in China, and insulin is the main treatment drug. The latest research shows that compound drug therapy has long-term effect on patients with type 2 diabetes, which is better than using a single drug. Generally speaking, the market demand of diabetes drugs is huge, the market prospect is broad, and there are good potential and development opportunities.